IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

 \supseteq

In re Applicat	tion of: Payne et al.	Atty Docket No.: IPT-060.02	130 (
Serial No:	09/292,411	Art Unit: 1645	30	
Filed:	April 15, 1999	Examiner: Navarro, Albert Ma	rk دِنِي	
For:	Fab I		S F	

CERTI	FICATE OF HAND DELIVERY					
I hereby certify that this Information Disclosure Statement is being submitted by hand delivery to Albert Mark Navarro, Patent and Trademark Office, Technology Center 1600, Crystal Mall 1, 7 th Floor, 1911 S. Clark Place, Arlington, VA 22202 on the date set forth below.						
October , 2003 Date of Signature and Hand Delivery	By: Name:					

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

<u>INFORMATION DISCLOSURE STATEMENT</u> <u>UNDER 37 CFR § 1.97 (b)(3)</u>

Sir:

Submitted herewith on Form PTO-1449 is a list of publications known to Applicants and/or their Attorney/Agent in compliance with the requirement of 37 C.F.R § § 1.56 and 1.97(c). A copy of each publicly available document is also being submitted herewith. At least three documents cited on accompanying Form 1449 contain sequence listings and/or large tables that are more than 50 pages in length. Applicants have submitted paper copies of these documents that do not include these large tables and/or listings. Following 37 C.F.R. 1.52 (e), Applicants have further submitted herewith, on compact disk, the entirety of documents WO 97/30070 (990 pages), EP 0786519 (3,271 pages) and US Patent No. 6,380,370 (267 pages). If the Examiner wishes to have full paper copies of these documents, the Examiner should contact the Attorney or Agent of record.

Applicants have cited for the Examiner's consideration certain issued U.S. patents and copending U.S. patent applications that are owned at least in part by the assignee of this application,

that describe subject matter related to the present invention. The co-pending applications are listed herewith in accordance with M.P.E.P. 609 III.D which states: "Applicants may wish to list U. S. patent application numbers on other than Form PTO-1449 or PTO/SB/08A and 08B format to avoid the application numbers of pending applications being published on the patent. If a citation is not printed on the patent but has been considered by the examiner in accordance with this section, the patented file will reflect that fact as noted in subsection III.C(2) above."

No copies of the co-pending applications have been provided. If the Examiner wishes to have copies of the co-pending applications, Examiner should contact the Attorney of record. Applicants respectfully request that the Examiner consider these listed documents and indicate that each was considered by making appropriate notations on this Information Disclosure Statement.

Examiner Initials	Our docket no.	S.N.	N. Title Filing Date		Status	Document Enclosed	
	IPT-064.01	10/407,028	Methods of Agonizing and Antagonizing Fab K	4 April 2003	Pending	no	
	IPT-060.01	08/790,043	Polynucleotide Encoding The Enoyl-Acyl Carrier Protein Reductase of Staphylococcus Aureus, Fab I (as Amended)	28 January 1997	pending	no	
	IPT-060.03	09/292,412	Polynucleotides Encoding Staphyloccal Fab I Enoyl- Acp Reductase (as Amended)	15 April 1999 13 August 2002	Issued: U.S. Pat. 6,432,670	yes	
	IPT-061.01	10/009,219	Methods of Using Fab I and Compounds Modulating Fab I Activity	4 May 2000	pending	no	
	IPT-062.01	10/089,019	Methods for Making and Using Fatty Acid Synthesis Pathway Reagents	26 October 2000	pending	no	
Date Consid	dered:		Examiner	r's Name:			

Applicants have listed dates of publication on the attached Form PTO-1449 for the cited documents based on information presently available to the undersigned. However, the listed publication dates should not be construed that the information in the cited documents was actually published or otherwise publicly available on the date indicated.

20/566493.1 - 2 -

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached Form PTO-1449.

This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that each or all of the listed documents are material or constitute "prior art." Further, if the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents. Moreover, the Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Although we believe that we have provided for the fee due in connection with this submission, the Commissioner is authorized to credit any overpayment or charge any deficiencies to/from our **Deposit Order Account No. 06-1448**.

Should there be any questions after reviewing this paper, the Examiner is invited to contact the undersigned at (617) 832-1000.

Respectfully submitted,

sylumes-

FOLEY HOAG LLP

Reg. No. 46,778 Agent for Applicants

Dated: October 29, 2003

Customer No.: 25181

Patent Group Foley Hoag LLP 155 Seaport Boulevard Boston, MA 02210-2600

Telephone: (617) 832-1000 Facsimile: (617) 832-7000

orm PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)				Docket IPT-06 Applic Payne	ant		pplication Number /292,411	Sheet Pa	50 1 01
				<u> </u>	15, 1999	16	oup Art Unit 45		
				U.S	S. PATENT DOCUMENTS	<u> </u>		Г	
EXAMINER INITIAL	DOCUMENT NUMBER		DOCUMENT NUMBER DATE		NAME	CLASS	SUBCLASS	FILING D IF APPROP	
	ВА	5, 539,132	07.23.9	96	Royer et al.				
	вв	5,614,551	03.25.9	97	Dick et al.				
	вс	5,759,837	06.02.9	98	Kuhajda et al.				
	BD	5,965,402	10.12.9	99	Black et al.			8	
	BE	6,228,619	05.08.0	01	Foster et al.			S	. 7
	BF	6,274,376	08.14.0	01	Black et al.			30	
	BG)2	Doucette-Stamm et al.				<u>.</u>
	вн)2	Bailey et al.			3	
	BI)2	Payne et al.			j j	
	ВЈ	US 2002/0076766	06.20.0)2	Black et al.				
	вк	6,593,114	07.15.0)3	Kunsch et al.				
			I	ORE	IGN PATENT DOCUMEN	TS			
	D	OCUMENT NUMBER	DATI	3	COUNTRY	CLASS	SUBCLASS	Translat YES	ion NO
	CA	DE 26 20 777	12.01.7	77	Germany				
	СВ	JP 10-174590	06.30.	98	Japan				
	СС	0 826 774 A2	04.03.	98	ЕРО				
	CD	0 78 6519 A2	07.30.	97	ЕРО				
	CE	WO 97/30070	08.21.9	97	PCT		4		
	CF	WO 97/30149	08.21.9	97	PCT			,	
		OTI	IER DO	CUMI	ENTS	(Including Au	ıthor, Title, Date, Per	tinent Pages Et	c.)
	FA	Bergler et al., "Protein E Vol. 269, No. 8, pp 5493			-dependent Enoyl-ACP Reductase (Fabl) of Escherichia co	oli*', The Journal of I	Biological Chen	nistry,
	FB	Bergler et al., "Sequence 2093-2100.	s of the en	M gene	and of two mutated alleles in Escherich	ia coli", Journal of	General Microbiolog	y (1992), 138, ₁	pp.
	FC	Broadwater et al., "Spina	ch Holo-A	cyl Carr	ier Protein: Overproduction and Phosph listidine-Tagged Isoform I ^{1"} , Protein Ex	opantetheinylation	in Escherichia coli B	L21(DE3), in V	'itro

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

DATE CONSIDERED

EXAMINER

are a f									Sheet Pa	age 2 of 3
Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)				Docke IPT-0	et Number (Optional) 60.02	cation Number 2,411				
				Applie	cant		1 33,03			
				Filing	Date		Groun	Art Unit		
**				April	15, 1999		1645		·····	
	,	···		U.S	S. PATENT DOCU	MENTS		T	EN DICT	DATE.
EXAMINER INITIAL	D	OCUMENT NUMBER	DATE	3	NAME	C	LASS	SUBCLASS	FILING I IF APPROF	
	<u> </u>			<u> </u>						
				ODE	ZIGN PATENT DO	CUMENTS				
	l D	OCUMENT NUMBER	DATE		COUNTRY		LASS	SUBCLASS	Transla	tion
		OCOMENT NOMBER	DAIL	-	COUNTRY		LAGO	SOBCLASS	YES	NO
	CG	WO 00/70017	11.23.0)0	PCT					
	СН	WO 01/30988	05.03.0)1	PCT					
	CI	WO 01/48248	07.05.0	01	PCT					
	Cì	WO 02/31128	04.18.0)2	PCT					
		ОТН	ER DO	CUM	ENTS	(Incli	ding Autho	or, Title, Date, Peri	inent Pages E	tc.)
-	FD	Edwards, et al., "Cloning of the fabF gene in an expression vector and in vitro characterization of recombinant fabF and fabB encoded enzyme from Escherichia coli", FEBS Letters, 402:62-66 (1997).								
	FE	Grassberger et al., "Prepara Chemistry, 1984. Vol. 24, l			cterial Activates of New 1,2,	3-Diazaborine Derivati	ves and An	alogues", Journal o	of Medicinal	
	FF	Gronowitz et al., "Antibacterial borazaro derivatives", Acta Pharm. Suecica 8, pp. 377-390 (1971).								
	FG	Heath et al., "Enoyl-Acyl Carrier Protein Reductase (fabl) Plays a Determinant Role in Completing Cycles of Fatty Acid Elongation in Escherichia coli*", The Journal of Biological Chemistry, Vol. 270, No. 44, pp. 26538-26542 (1995).								
	FH	Heath et al., "Regulation of Fatty Acid Elongation and Initiation by Acyl-Acyl Carrier Protein in Escherichia coli*", The Journal of Biologica Chemistry, Vol. 271, No. 4, pp 1833-1836 (1996).								gical
	FI	Lam et al., "Effect of diazaborine derivative (Sa 84.474) on the virulence of Escherichia coli", Journal of Antimicrobial Chemotherapy (1987) pp. 37-45.								87) 20,
	FJ	Lambalot, et al., "Cloning, Over production, and Characterization of the Escherichia coli Holo-acyl Carrier Protein Synthase*", The Journal of Biological Chemistry, Vol. 270, No. 42, pp. 24658-24661 (1995).								al of
	FK	Ngo et al., "Computational complexity, protein structure prediction, and the Levinthal paradox", Chapter 14 in 'The Protein Folding Problem and Tertiary Structure Prediction', Merz et al. (eds.), Birkhauser: Boston, MA, pp. 433 & 492-495.								em and
	FL	Rock et al., "Preparative Enzymatic Synthesis and Hydrophobic Chromatography of Acyl-Acyl Carrier Protein", <i>The Journal of Biological Chemistry</i> , 254(15): 7123-7128 (1979).								1
EXAMINER	_		•			DATE CONSIDERED				
l	1				i					

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

									Sheet Pag	ge 3 of 3		
Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)				Docket Number (Optional) Application Number IPT-060.02 09/292,411								
				Applicant Payne et al								
				Filing Date				Group Art Unit				
				April 15,			1645					
EXAMINER				U.S. 1	PATENT DOCU	MENTS		T	FILING D	A TE		
INITIAL	D	DOCUMENT NUMBER DATE NA			NAME		CLASS	SUBCLASS	IF APPROPE			
			F	OREIG	N PATENT DO	CUMENTS	i					
	D	OCUMENT NUMBER	DATE		COUNTRY		CLASS	SUBCLASS	Translati YES	on NO		
			-						123	NO		
								<u>.</u>				
		ОТН	ER DOC	CUMEN	TS		(Including Autho	r, Title, Date, Pert	inent Pages Etc	:.)		
								· · · · · · · · · · · · · · · · · · ·				
	FM	Rock et al., "Acyl Carrier P	Protein from	m <i>Escheri</i>	chia coli", Methods in E	nzymology, 71:3	41-351 (1981).					
	FN		Roujeinkova et al., "Inhibitor Binding Studies on Enoyl Reductase Reveal Conformational Changes Related to Substrate Recognition", <i>The Journal of Biological Chemistry</i> , 274(43): 30811-30817 (1999).									
		Journal of Biological Chem	usiry, 214									
	FO	Turnowsky et al., "envM ge	Turnowsky et al., "envM genes of Salmonella typhimurium and Escherichia coli", Journal of Bacteriology, Dec. 1989 pp. 6555-6565.									
	FP	Ward et al., "Kinetic and St 12514-12525 (1999).	tructural C	Characteris	tics of the Inhibition of l	Enoyl (Acyl Carr	ier Protein) Reduc	tase by Triclosan"	, Biochemistry,	38:		
									<u></u>			
				· · ·				<u> </u>				
					-							
EXAMINER						DATE CONSIDI	ERED	• • • •				
EXAMINER: I conformance ar	Initia nd no	al if citation considered, woot considered. Include cop	hether or	r not citat form wit	ion is in conformance h next communication	with MPEP § to the applica	609; Draw line nt.	through citation	if not in			

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE